Physician profile
Brian Feingold
NPI 1811059108
$1,205.86
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,206.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $291.39 | 2019 | |
| Amgen INC. | $157.65 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $136.13 | 2019 | |
| Genzyme Corporation | $110.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $103.71 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.26 | 2019 | |
| Astellas Pharma US INC | $54.02 | 2019 | |
| Edwards Lifesciences Corporation | $53.62 | 2019 | |
| Merck Sharp & Dohme LLC | $42.36 | 2019 | |
| Glaxosmithkline, LLC. | $41.04 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $39.18 | 2019 | |
| Daiichi Sankyo INC. | $21.87 | 2019 | |
| Abbott Laboratories | $16.26 | 2019 | |
| Promius Pharma LLC | $13.30 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.81 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12.26 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Feingold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.